πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Collegium Pharmaceutical, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

XTreo technology platform

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company developing integrated drug and delivery solutions for ear, nose, and throat diseases using its XTreo technology platform. It focuses on product candidates like LYR-210 and LYR-220 for chronic rhinosinusitis.

Tags: biotechnology, chronic rhinosinusitis, drug delivery, healthcare, therapeutics

Symbol: LYRA

Recent Price: $0.22

Industry: Biotechnology

CEO: Dr. Maria Palasis Ph.D.

Sector: Healthcare

Employees: 88

Address: 480 Arsenal Way, Watertown, MA 02472

Phone: 617 393 4600

Leadership

  • Harlan W. Waksal, M.D., Executive Chairman
  • Maria Palasis, Ph.D., President and Chief Executive Officer
  • Jason Cavalier, Chief Financial Officer
  • Robert Kern, M.D., Chief Clinical Advisor
  • Ronan O’Brien, Chief Legal Officer
  • Vineeta Belanger, Ph.D., Senior Vice President of Clinical Affairs
  • Gloria Cosgrove, Senior Vice President of Quality
  • Allison Nance, Senior Vice President of Regulatory Affairs
  • Michael Altman, CFA, Managing Director, Perceptive Advisors
  • Ann Merrifield, Life Sciences Advisor and Board Director
  • Konstantin Poukalov, Managing Director, Perceptive Advisors
  • Bradford Smith, Board Director
  • Nancy L. Snyderman, M.D., Board Director
  • Jim Tobin, Lead Independent Director
  • Robert Langer, D.Sc., David H. Koch Institute Professor, Massachusetts Institute of Technology
  • George Whitesides, Ph.D., Woodford L. and Ann A. Flowers University Professor, Harvard University

Last updated: 2024-12-31

NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ZYESAMI, NRX-100, NRX-101

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.

Tags: CNS disorders, COVID-19 treatment, bipolar depression, clinical-stage pharmaceutical, pulmonary diseases, suicidal behavior

Symbol: NRXP

Recent Price: $1.53

Industry: Biotechnology

CEO: Dr. Jonathan C. Javitt M.D., M.P.H.

Sector: Healthcare

Employees: 2

Address: 1201 Orange Street, Wilmington, DE 19801

Phone: 484 254 6134

Last updated: 2024-12-31

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

SNDX-5613, SNDX-6352 (axatilimab), Entinostat

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer treatment, including innovative candidates like SNDX-5613 and SNDX-6352. It collaborates with notable institutions like the National Cancer Institute and has a license agreement with Kyowa Hakko Kirin Co., Ltd.

Tags: Collaborations, Entinostat, Monoclonal Antibody, SNDX-5613, SNDX-6352, biopharmaceutical, cancer therapy, clinical-stage

Symbol: SNDX

Recent Price: $12.52

Industry: Biotechnology

CEO: Mr. Michael A. Metzger M.B.A.

Sector: Healthcare

Employees: 184

Address: 35 Gatehouse Drive, Waltham, MA 02451

Phone: 781 419 1400

Last updated: 2024-12-31

Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TNX-103, TNX-102 (levosimendan), TNX-201 (imatinib)

Tenax Therapeutics, Inc. is a specialty pharmaceutical company that focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases. The company is involved in developing medications such as TNX-103 and TNX-102 (levosimendan) for pulmonary hypertension and heart failure, and TNX-201 (imatinib) for pulmonary arterial hypertension.

Tags: TNX-102, TNX-103, TNX-201, cardiovascular, pharmaceutical, pulmonary diseases

Symbol: TENX

Recent Price: $6.55

Industry: Biotechnology

CEO: Mr. Christopher T. Giordano

Sector: Healthcare

Employees: 5

Address: ONE Copley Parkway, Morrisville, NC 27560

Phone: 919 855 2100

Last updated: 2024-12-31

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. logo
Market Cap: Lowest
Employees: Low

TNX-1500, TNX-2900, TNX-801, TNX-1840, TNX-1850, TNX-3500

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company that focuses on developing therapies for immunology, rare diseases, infectious diseases, and central nervous system disorders. Key products include TNX-1500 for organ transplant and autoimmune diseases, TNX-2900 for Prader-Willi syndrome, and TNX-801 for smallpox prevention.

Tags: CNS, autoimmunity, biopharmaceutical, cancer, immunology, infectious disease, rare disease, therapeutics

Symbol: TNXP

Recent Price: $0.36

Industry: Biotechnology

CEO: Dr. Seth Lederman M.D.

Sector: Healthcare

Employees: 103

Address: 26 Main Street, Chatham, NJ 07928

Phone: 862 799 8599

Last updated: 2024-12-31

Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

Sympazan, Suboxone, Zuplenz, Azstarys, Libervant, Exservan

Aquestive Therapeutics, Inc. is a pharmaceutical company committed to identifying, developing, and commercializing innovative products to address unmet medical needs, both in the U.S. and globally. It specializes in oral soluble film formulations for various treatments, including neurological conditions and opioid dependence.

Tags: ADHD, ALS, biotechnology, neurology, opioid dependence, oral soluble film, pharmaceutical

Symbol: AQST

Recent Price: $3.52

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Daniel Barber

Sector: Healthcare

Employees: 135

Address: 30 Technology Drive, Warren, NJ 07059

Phone: 908 941 1900

Last updated: 2024-12-31

Ardelyx, Inc.

Ardelyx, Inc. logo
Market Cap: High
Employees: Low

tenapanor

Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for gastrointestinal and cardiorenal therapeutic areas, including treatments for irritable bowel syndrome with constipation and hyperphosphatemia.

Tags: CKD, biopharmaceutical, cardiorenal, gastrointestinal, hyperkalemia, hyperphosphatemia, metabolic acidosis, tenapanor

Symbol: ARDX

Recent Price: $5.25

Industry: Biotechnology

CEO: Mr. Michael G. Raab

Sector: Healthcare

Employees: 267

Address: 400 Fifth Avenue, Waltham, MA 02451

Phone: 510 745 1700

Leadership

  • Justin Renz, Chief Financial & Operations Officer
  • Eric Foster, Chief Commercial Officer
  • Elizabeth Grammer, Esq., Chief Legal & Administrative Officer
  • Laura Williams, MD MPH, Chief Medical Officer
  • Robert Blanks, MS RAC, Chief Regulatory Affairs & Quality Assurance Officer
  • David Rosenbaum, PhD, Chief Development Officer
  • Mike Kelliher, Executive Vice President, Corporate Development and Strategy
  • Charon Spencer, Chief Human Resources Officer
  • David Mott, Chairman
  • Robert Bazemore, Director
  • William A. Bertrand, Jr., JD, Director
  • Muna Bhanji, R.Ph, Director
  • Onaiza Cadoret-Manier, Director
  • Mike Raab, Director
  • Richard Rodgers, Director

Last updated: 2024-12-31

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

AXS-05, AXS-07, AXS-12, AXS-14

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders such as major depressive disorder, migraine, narcolepsy, and fibromyalgia.

Tags: CNS disorders, biopharmaceutical, clinical trials, depression, fibromyalgia, migraine, narcolepsy

Symbol: AXSM

Recent Price: $84.78

Industry: Biotechnology

CEO: Dr. Herriot Tabuteau M.D.

Sector: Healthcare

Employees: 589

Address: 22 Cortlandt Street, New York, NY 10007

Phone: 212 332 3241

Leadership

  • Herriot Tabuteau, MD, CHIEF EXECUTIVE OFFICER
  • Nick Pizzie, CPA, MBA, CHIEF FINANCIAL OFFICER
  • Mark Jacobson, MA, CHIEF OPERATING OFFICER
  • Hunter Murdock, Esq., GENERAL COUNSEL
  • ari Maizel, Executive Vice President, Head of Commercial
  • Mark Coleman, MD, DIRECTOR
  • Roger Jeffs, PhD, DIRECTOR
  • Susan Mahony, PhD, MBA, DIRECTOR
  • Mark Saad, DIRECTOR

Last updated: 2024-12-31

Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. logo
Market Cap: Medium
Employees: Low

Xtampza ER, Nucynta ER, Nucynta IR

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company that develops and commercializes medicines focused on pain management, with a notable portfolio including Xtampza ER and Nucynta formulations.

Tags: medicines, opioid treatment, pain management, pharmaceutical, specialty pharma

Symbol: COLL

Recent Price: $28.61

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.

Sector: Healthcare

Employees: 197

Address: 100 Technology Center Drive, Stoughton, MA 02072

Phone: 781 713 3699

Last updated: 2024-12-31

Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. logo
Market Cap: Lowest
Employees: Low

Acetadote, Caldolor, Kristalose, Omeclamox-Pak, Vaprisol, Vibativ, Redi Trex

Cumberland Pharmaceuticals Inc. focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology, offering various medications including injections and oral solutions.

Tags: gastroenterology, hospital care, oncology, pharmaceutical, prescription products, rheumatology

Symbol: CPIX

Recent Price: $2.42

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. A. J. Kazimi MBA

Sector: Healthcare

Employees: 91

Address: 2525 West End Avenue, Nashville, TN 37203

Phone: 615 255 0068

Last updated: 2024-12-31

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated logo
Market Cap: High
Employees: Lowest

Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.

Tags: biopharmaceutical, commercial programs, disease treatment, medicine development, pharmaceutical technology

Symbol: LGND

Recent Price: $105.76

Industry: Biotechnology

CEO: Mr. Todd C. Davis Ph.D.

Sector: Healthcare

Employees: 58

Address: 5980 Horton Street, EmeryVille, CA 94608

Phone: 858 550 7500

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Pacira BioSciences, Inc.

Pacira BioSciences, Inc. logo
Market Cap: Medium
Employees: Medium

EXPAREL, ZILRETTA, iovera

Pacira Bio Sciences, Inc. offers non-opioid pain management and regenerative health solutions. Products include EXPAREL, ZILRETTA, and the iovera system. The company focuses on drug delivery technology with a proprietary multivesicular liposome system.

Tags: drug delivery, healthcare, non-opioid, pain management, regenerative health

Symbol: PCRX

Recent Price: $18.94

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Frank D. Lee

Sector: Healthcare

Employees: 711

Address: 5401 West Kennedy Boulevard, Tampa, FL 33609

Phone: 813 553 6680

Leadership

  • Frank D. Lee, Chief Executive Officer and member of the Board of Directors
  • Paul J Hastings, Chair of the Board of Directors
  • Marcelo Bigal, MD, PhD, President and Chief Executive Officer of Ventus Therapeutics
  • Laura Brege, Former CEO of Nodality, Inc.
  • Abraham Ceesay, Chief Executive Officer of Rapport Therapeutics
  • Chris Christie, Director
  • Mark I. Froimson, MD, Principal at Riverside Health Advisors
  • Mark Kronenfeld, MD, Chairman of Anesthesiology at Maimonides Medical Center
  • Andreas Wicki, PhD, Chief Executive Officer of HBM Healthcare Investments AG
  • Michael Yang, Former Chief Executive Officer of ViaCyte
  • Alethia Young, Chief Financial Officer of Bicycle Therapeutics

Last updated: 2024-12-31

scPharmaceuticals Inc.

scPharmaceuticals Inc. logo
Market Cap: Low
Employees: Low

FUROSCIX

sc Pharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing pharmaceutical products, with a lead product candidate, FUROSCIX, aimed at treating congestion in heart failure patients using an on-body infusor.

Tags: antibiotics, drug development, healthcare, heart failure, pharmaceuticals

Symbol: SCPH

Recent Price: $3.50

Industry: Biotechnology

CEO: Mr. John H. Tucker

Sector: Healthcare

Employees: 135

Address: 2400 District Avenue, Burlington, MA 01803

Phone: 617 517 0730

Leadership

  • John H. Tucker, President and Chief Executive Officer
  • Rachael Nokes, Chief Financial Officer
  • Mike Hassman, Senior Vice President, Technical Operations
  • John Mohr, Pharm.D., FIDP, Senior Vice President, Clinical Development and Medical Affairs
  • William T. Abraham, MD,
  • Mette Kirstine Agger, Co-Founder & CEO, 7TM Pharma A/S
  • Minnie V. Baylor-Henry, President, B-Henry & Associates
  • Sara Bonstein, CFO, Insmed Incorporated
  • Frederick Hudson, Former Partner in Charge of KPMG’s Largest Healthcare Industry Audit Practice Located in the Mid-Atlantic Region
  • Jack A. Khattar, Founder, President & Chief Executive Officer, Supernus Pharmaceuticals
  • Leonard D. Schaeffer, Founding Chairman & CEO, Wellpoint
  • Klaus Veitinger, MD, PhD, Venture Partner, Orbimed
  • Dan Bensimhon, MD, Medical Director Advanced Heart Failure & Mechanical Circulatory Support Program, Cone Health, Greensboro, NC
  • G. Michael Felker, MD, Chief, Heart Failure Service, Division of Cardiology, Duke University School of Medicine
  • Marv Konstam, MD, Professor of Medicine, Tufts University School of Medicine, Chief Physician Executive of the Cardiovascular Center at Tufts Medical Center
  • W. Frank Peacock, MD, FACEP, FACC, FESC, Professor, Vice Chair of Research, Department of Emergency Medicine, Baylor College of Medicine, Ben Taub General Hospital
  • Stuart Russell, MD, Regional Director of Heart Failure Program, Duke University School of Medicine
  • James E. Udelson, MD, Chief, Division of Cardiology, Tufts Medical Center, Professor of Medicine and Radiology Tufts University School of Medicine
  • William Weintraub, MD, Director of Outcomes Research, MedStar Heart and Vascular Institute

Last updated: 2024-12-31

Silo Pharma, Inc.

Silo Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

SPC-15

Silo Pharma Inc. is a developmental stage biopharmaceutical company focusing on treatments for stress-induced psychiatric disorders, chronic pain, and CNS diseases through traditional and psychedelic therapies.

Tags: CNS diseases, biopharmaceutical, chronic pain, psychedelic treatments, psychiatric disorders, traditional therapies

Symbol: SILO

Recent Price: $0.89

Industry: Biotechnology

CEO: Mr. Eric Weisblum

Sector: Healthcare

Employees: 3

Address: 677 N. Washington Boulevard, Sarasota, FL 34236

Phone: 718 400 9031

Last updated: 2024-12-31

Talphera, Inc.

Talphera, Inc. logo
Market Cap: Lowest
Employees: Lowest

Niyad

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company develops products like Niyad, LTX-608, Fedsyra, and PFS-02, with applications in anticoagulant, anti-inflammatory, and antiviral treatments.

Tags: anti-inflammatory, anticoagulants, antiviral, healthcare, pharmaceuticals

Symbol: TLPH

Recent Price: $0.54

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Vincent J. Angotti

Sector: Healthcare

Employees: 15

Address: 1850 Gateway Drive, San Mateo, CA 94404

Phone: 650 216 3500

Last updated: 2024-12-31

Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

Epoladerm, Probudur, Envelta, PES200, An Qlar, VRP324

Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company dedicated to developing drug-delivery systems and technologies for non-opioid, non-addictive pain management and treatments for central nervous system disorders.

Tags: Envelta, Epoladerm, Probudur, central nervous system, drug-delivery, non-opioid, pain management, pharmaceutical, preclinical

Symbol: VRPX

Recent Price: $0.45

Industry: Biotechnology

CEO: Mr. Jatinder Dhaliwal

Sector: Healthcare

Employees: 7

Address: 1055 Westlakes Drive, Berwyn, PA 19312

Phone: 610 727 4597

Last updated: 2024-12-31

Avenue Therapeutics, Inc.

Avenue Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

intravenous Tramadol

Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the acute/intensive care hospital setting. The company is advancing intravenous Tramadol, a synthetic dual-acting opioid, in Phase III clinical trials for post-operative acute pain treatment.

Tags: acute care, clinical trials, intensive care, intravenous Tramadol, opioids, pain management, pharmaceutical

Symbol: ATXI

Recent Price: $1.94

Industry: Biotechnology

CEO: Dr. Alexandra MacLean M.D.

Sector: Healthcare

Employees: 3

Address: 1140 Avenue of the America, New York, NY 10036

Phone: 781 652 4500

Leadership

  • Jay Kranzler, MD, PhD, Chairman of the Board of Directors
  • Alexandra MacLean, MD, Director
  • David Jin, Interim Chief Financial Officer
  • Scott A. Reines, MD, PhD, Interim Chief Medical Officer
  • Michael Ryan, MS, Vice President of Clinical Operations and Program Management
  • Alix MacLean, Chief Executive Officer
  • Lindsay A. Rosenwald, MD, Director
  • Neil Herskowitz, Director
  • Curtis Oltmans, Director
  • Faith Charles, Director

Last updated: 2024-12-31

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. logo
Market Cap: Low
Employees: Lowest

NXP800, NXP900

Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.

Tags: NXP800, NXP900, biopharmaceutical, oncology, precision medicine

Symbol: NVCT

Recent Price: $5.14

Industry: Biotechnology

CEO: Mr. Ron Bentsur M.B.A.

Sector: Healthcare

Employees: 13

Address: 1 Bridge Plaza, Fort Lee, NJ 07024

Phone: 201 614 3150

Last updated: 2024-12-31